Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
Core Innovation
The disclosure describes a humanized anti-BCMA single-chain variable fragment (scFv) and a chimeric antigen receptor (CAR) incorporating that scFv. The CAR includes a CD8 leader and hinge, a CD28 transmembrane domain and co-stimulatory domain, and a CD3ζ activating domain. The disclosed CAR-T cells are directed against BCMA-positive targets, including multiple myeloma cells.
The provided material reports that the CAR-T cells selectively kill BCMA-positive cells, produce IFN-γ against BCMA-positive targets, and spare BCMA-negative controls. It also reports reduced tumor growth in an RPMI8226 xenograft model without reduced mouse body weight. The supplied partial content does not include the background section, so the problem being addressed is not explicitly described.
Claims Coverage
The relevant claims include three independent claims: an anti-BCMA scFv, an anti-BCMA CAR, and a method of killing BCMA-overexpressing multiple myeloma cancer cells.
Anti-BCMA scFv
The scFv comprises a heavy chain variable region comprising SEQ ID NO: 3 and a light chain variable region comprising SEQ ID NO: 5.
Anti-BCMA CAR
The CAR comprises the specified anti-BCMA scFv, a transmembrane domain, a co-stimulatory domain, and an activating domain.
Killing BCMA-overexpressing multiple myeloma cancer cells
The method comprises contacting BCMA-overexpressing multiple myeloma cancer cells with a CAR-T cell comprising the specified anti-BCMA scFv, a transmembrane domain, a co-stimulatory domain, and an activating domain.
The independent claims cover the specified anti-BCMA scFv, a CAR incorporating that scFv and three receptor domains, and use of a CAR-T cell comprising those elements to kill BCMA-overexpressing multiple myeloma cancer cells.
Stated Advantages
The CAR-T cells selectively kill BCMA-positive cells while sparing BCMA-negative controls.
In the reported RPMI8226 xenograft model, treatment significantly reduces tumor growth without reducing mouse body weight.
Documented Applications
Use against BCMA-positive multiple myeloma, including killing BCMA-overexpressing multiple myeloma cancer cells with CAR-T cells.
The disclosure identifies other cancers as applications of the CAR-T cells.
Interested in licensing this patent?